Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Stemming vision loss with stem cells
Valentina Marchetti, … , David F. Friedlander, Martin Friedlander
Valentina Marchetti, … , David F. Friedlander, Martin Friedlander
Published September 1, 2010
Citation Information: J Clin Invest. 2010;120(9):3012-3021. https://doi.org/10.1172/JCI42951.
View: Text | PDF
Review

Stemming vision loss with stem cells

  • Text
  • PDF
Abstract

Dramatic advances in the field of stem cell research have raised the possibility of using these cells to treat a variety of diseases. The eye is an excellent target organ for such cell-based therapeutics due to its ready accessibility, the prevalence of vasculo- and neurodegenerative diseases affecting vision, and the availability of animal models to demonstrate proof of concept. In fact, stem cell therapies have already been applied to the treatment of disease affecting the ocular surface, leading to preservation of vision. Diseases in the back of the eye, such as macular degeneration, diabetic retinopathy, and inherited retinal degenerations, present greater challenges, but rapidly emerging stem cell technologies hold the promise of autologous grafts to stabilize vision loss through cellular replacement or paracrine rescue effects.

Authors

Valentina Marchetti, Tim U. Krohne, David F. Friedlander, Martin Friedlander

×

Figure 2

BM-derived Lin– HSC injection rescues the degeneration of vascular and neural cells in a mouse model of retinal degeneration (rd1/rd1).

Options: View larger image (or click on image) Download as PowerPoint
BM-derived Lin– HSC injection rescues the degeneration of vascular and n...
Retinal vasculature (green, stained for CD31) is well preserved in the Lin–-treated eye (A) and is degenerated except for small numbers of the superficial plexus in control-treated eyes (B). Neurotrophic rescue is also observed whenever the vasculature is rescued; in the control-treated eye (B), the outer nuclear layer (ONL) is completely degenerated and the inner nuclear layer (INL) atrophic. Retinal function is also preserved after Lin- HSC. GCL, ganglion cell layer. From the JCI (66).

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts